Overview

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

This study is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable locally advanced or metastatic HER2-positive breast cancer who had failed previous treatment with taxanes and trastuzumab.

Phase:

PHASE3

Details

Lead Sponsor:

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborator:

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.